Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-17

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.

CTCs will be isolated from peripheral blood before antineoplastic treatment and again after three months. Isolation using HSP70 will be compared with standard CTC isolation by EpCAM.

Additionally, imaging parameters of the primary tumor (if available) and metastases will be analysed and correlations between molecular alterations and imaging parameters will be assesed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma

NCT06863870

Melanoma Neoplasms

ACTIVE_NOT_RECRUITING

The Role of Hypoxia as a Selective Pressure for TP53 Mutations

NCT03466034

Endometrial Cancer

TERMINATED

Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease

NCT02781025

Circulating Tumor Cells

COMPLETED

Circulating Tumor Cells (CTC) in Cancer

NCT04520672

Cancer

RECRUITING

Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer

NCT02610218

Gastric Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Stage IV Sarcoma Squamous Cell Carcinoma Pancreatic Cancer Stage IV Prostate Cancer Breast Cancer Stage IV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HSP70CTC

Isolation of circulating tumor cells by HSP70

CTC isolation by HSP70

Intervention Type DIAGNOSTIC_TEST

patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTC isolation by HSP70

patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Metastatic malignant melanoma (stage IV)
* Metastatic or unresectable pancreatic adenocarcinoma (stage III or IV)
* Metastatic breast cancer
* Metastatic sarcoma
* Metastatic squamous cell carcinoma of the cervix uteri, head and neck region, vulva, anus or penis
* hormone-refractory prostate cancer